A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

Inclusion Criteria: * Documented diagnosis of NDO, confirmed by urodynamics * Practicing clean intermittent catheterization (CIC) * Currently on treatment with an antimuscarinic drug Exclusion Criteria: * Known genitourinary condition (other than NDO) that may cause incontinence * Bladder augmentation surgery * Current Faecal impaction * Electro-stimulation therapy within 2 weeks prior to screening and at any time during the study * Subjects with the following gastro-intestinal problems: partial or complete obstruction, decreased motility like paralytic ileus, subjects at risk of gastric retention * Reflux grade 3 or 4 * Current urinary tract infection (UTI) * Subject has severe renal impairment (glomerular filtration rate \< 30 ml/min) * Subject has severe hepatic impairment (Child-Pugh score \> 9). * Subject has received intra-vesical botulinum toxin within 9 months prior to screening